Therefore, we speculate that the significantly higher proportion of BAP1 mutation in the m5C scorehigh cluster contributes to the poor prognosis for ccRCC patients, and the low proportion of PBRM1 mutations in the immune-desert phenotype may reflect reduced immunotherapy efficiency of ccRCC patients. Here, BAP1 is linked to nonpapillary renal cell carcinoma.